Advanced Proteome Therapeutics (TSXV:APC.H) Research & Development: C$0.80 Mil (TTM As of Apr. 2023)


What is Advanced Proteome Therapeutics Research & Development?

Advanced Proteome Therapeutics TSXV:APC.H Research & Development is C$0.80 Mil as of Apr. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Advanced Proteome Therapeutics's Research & Development for the three months ended in Apr. 2023 was C$0.12 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Apr. 2023 was C$0.80 Mil.

Advanced Proteome Therapeutics  (TSXV:APC.H) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Advanced Proteome Therapeutics Research & Development Related Terms

Advanced Proteome Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Research & Development Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.49 0.89

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 0.24 0.22 0.12

Advanced Proteome Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.80 Mil mean?
Advanced Proteome Therapeutics (TSXV:APC.H) has a Research & Development of C$0.80 Mil as of Apr. 2023. Research and development expense is the total cost for research and development activities. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Research & Development too high?
Advanced Proteome Therapeutics' current Research & Development is C$0.80 Mil.
How does Advanced Proteome Therapeutics' Research & Development compare to VRTX and REGN?
Advanced Proteome Therapeutics' Research & Development of C$0.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Research & Development is C$0.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (TSXV:APC.H) has a current Research & Development of C$0.80 Mil. The current Research & Development is C$0.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Advanced Proteome Therapeutics (TSXV:APC.H), the current Research & Development is C$0.80 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.